Pfizer Files Proxy Supplement for 2024 Annual Meeting

TL;DR

Pfizer dropped more proxy docs for the 2024 meeting. No fee.

AI Summary

Pfizer Inc. filed a Definitive Additional Materials proxy statement (DEFA14A) on March 28, 2024, supplementing its Notice of 2024 Annual Meeting. This filing is related to the company's proxy materials and does not involve a fee, as indicated by the 'No fee required' checkbox. The filing is made under the 1934 Securities Exchange Act.

Why It Matters

This filing provides additional information to shareholders regarding the upcoming 2024 Annual Meeting, ensuring they have the necessary details for voting on company matters.

Risk Assessment

Risk Level: low — This is a routine administrative filing related to proxy materials for an annual meeting, not indicating any immediate financial or operational risks.

Key Players & Entities

• Pfizer Inc. (company) — Registrant
• 0000078003-24-000086 (filing_id) — Accession Number
• 20240328 (date) — Filing Date

FAQ

Filing Documents

• pfe_-xproxyxsupplement1224.htm (DEFA14A) — 14KB
• pfizerlogoaa.jpg (GRAPHIC) — 38KB
• 0000078003-24-000086.txt ( ) — 62KB

From the Filing

PFIZER SUPPLEMENT PROXY Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant Check the Appropriate Box Preliminary Proxy Statement Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement x Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 Pfizer Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of filing fee (Check all boxes that apply) x No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 66 Hudson Boulevard East New York, New York 10001 SUPPLEMENT TO NOTICE OF 2024 ANNUAL MEETING AND PROXY STATEMENT FOR THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 25, 2024 March 28, 2024 This Supplement provides updated information with respect to the 2024 Annual Meeting of Shareholders (the "Annual Meeting") of Pfizer Inc. ("Pfizer") to be held on April 25, 2024. On March 14, 2024, Pfizer commenced distribution of the Notice of Annual Meeting and Proxy Statement (the "Proxy Statement") for the Annual Meeting and notice of availability of the Proxy Statement. This Supplement should be read in conjunction with the Proxy Statement. Withdrawal of Shareholder Proposal The proponent of Item 7 – Amend Director Resignation Processes ("Item 7") has withdrawn the proposal. Therefore, Item 7 will not be presented or voted upon at the Annual Meeting, nor will any votes cast in regard to Item 7 be tabulated or reported. Voting Matters Notwithstanding the withdrawal of Item 7, the proxy card and voting instruction forms distributed or presented online with the Proxy Statement remain valid, and Pfizer will not distribute new voting instructions or proxy cards. None of the other agenda items presented in the Proxy Statement are affected by this Supplement, and shares represented by proxy cards or voting instruction forms returned before the Annual Meeting will be voted with respect to all other matters properly brought before the Annual Meeting as instructed on the proxy card or voting instruction form. If you have already returned your proxy card or voting instruction form, you do not need to take any action unless you wish to change your vote. If you have not yet returned your proxy card or voting instruction form, please complete the proxy card or voting instruction form, disregarding Item 7. Information on how to vote your shares, or change or revoke your prior vote or voting instruction, is available in the Proxy Statement.

View Full Filing

View this DEFA14A filing on SEC EDGAR